Product Description
Azasetron (Serotone) is a potent and selective 5-HT3 receptor antagonist, and classified as benzamide derivative. It has a different chemical structure from indole-type 5-HT3 receptor antagonists such as granisetron, ondansetron, ramosetron and tropisetron. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/10396331/)
Mechanisms of Action: 5-HT3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sensorion
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2300078516 | N/A |
Not yet recruiting |
Anesthesia Related |
2026-08-31 |
|
ChiCTR2300076786 | N/A |
Not yet recruiting |
Unknown |
2024-10-20 |
|
ChiCTR2200060139 | N/A |
Not yet recruiting |
Chronic Pain|Pain, Postoperative |
2023-12-31 |
|
ChiCTR2100049246 | N/A |
Not yet recruiting |
Other |
2021-12-31 |